Shree Ram Proteins 미래 성장

Future 기준 확인 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shree Ram Proteins.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Food 수익 성장	16.3%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

업데이트 없음

Recent updates

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Feb 28

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Mar 29

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Dec 11

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Nov 06

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Jun 19

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Feb 24

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Shree Ram Proteins 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

NSEI:SRPL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2024	57	-103	N/A	N/A	N/A
3/31/2024	148	-96	6	6	N/A
12/31/2023	391	-53	N/A	N/A	N/A
9/30/2023	768	-2	27	27	N/A
6/30/2023	1,195	27	N/A	N/A	N/A
3/31/2023	1,627	38	-214	-202	N/A
12/31/2022	2,367	52	N/A	N/A	N/A
9/30/2022	2,688	59	126	139	N/A
6/30/2022	3,012	65	N/A	N/A	N/A
3/31/2022	2,878	61	360	363	N/A
12/31/2021	2,699	79	N/A	N/A	N/A
9/30/2021	2,527	64	54	56	N/A
6/30/2021	1,817	33	N/A	N/A	N/A
3/31/2021	1,526	8	8	9	N/A
12/31/2020	1,468	-11	N/A	N/A	N/A
9/30/2020	1,248	-13	-26	-26	N/A
6/30/2020	1,404	7	14	14	N/A
3/31/2020	1,559	26	54	54	N/A
12/31/2019	1,273	19	N/A	N/A	N/A
9/30/2019	1,429	38	51	51	N/A
6/30/2019	1,505	36	65	68	N/A
3/31/2019	1,581	33	79	85	N/A
12/31/2018	1,853	26	-1	8	N/A
9/30/2018	2,127	19	-83	-70	N/A
6/30/2018	2,040	19	-113	-104	N/A
3/31/2018	1,954	18	N/A	-137	N/A
3/31/2017	1,574	6	N/A	72	N/A
3/31/2016	1,833	5	N/A	12	N/A
3/31/2015	1,744	14	N/A	94	N/A
3/31/2014	1,573	13	N/A	-130	N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if SRPL's forecast earnings growth is above the savings rate (6.7%).

수익 vs 시장: Insufficient data to determine if SRPL's earnings are forecast to grow faster than the Indian market

고성장 수익: Insufficient data to determine if SRPL's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: Insufficient data to determine if SRPL's revenue is forecast to grow faster than the Indian market.

고성장 수익: Insufficient data to determine if SRPL's revenue is forecast to grow faster than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if SRPL's Return on Equity is forecast to be high in 3 years time

Shree Ram Proteins 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

First quarter 2025 earnings released: ₹0.02 loss per share (vs ₹0.01 profit in 1Q 2024)

Full year 2024 earnings released: ₹0.45 loss per share (vs ₹0.18 profit in FY 2023)

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Now 22% overvalued after recent price rise

Now 24% overvalued after recent price rise

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Less than half of directors are independent

Shree Ram Proteins Limited Announces the Resignation of Jaykumar Deepakbhai Khatnani as Independent Director

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹0.09 loss per share (vs ₹0.048 profit in 2Q 2023)

Shree Ram Proteins Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 16%

Shree Ram Proteins Limited, Annual General Meeting, Aug 14, 2023

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Less than half of directors are independent

Full year 2023 earnings released: EPS: ₹0.18 (vs ₹0.29 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: ₹1.79 (vs ₹2.87 in FY 2022)

Investor sentiment improves as stock rises 16%

Chairman & MD recently sold ₹15m worth of stock

Chairman & MD recently sold ₹22m worth of stock

Shree Ram Proteins (NSE:SRPL) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorates as stock falls 17%

Chairman & MD recently sold ₹4.9m worth of stock

Third quarter 2023 earnings released: EPS: ₹0.25 (vs ₹0.56 in 3Q 2022)

Chairman & MD recently sold ₹2.0m worth of stock

Investor sentiment deteriorated over the past week

Non Executive Director recently sold ₹7.3m worth of stock

Non Executive Director recently bought ₹40m worth of stock

Insider recently sold ₹2.4m worth of stock

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Investor sentiment improved over the past week

Insider recently sold ₹1.7m worth of stock

Chairman & MD recently bought ₹2.4m worth of stock

Second quarter 2023 earnings released: EPS: ₹0.48 (vs ₹0.77 in 2Q 2022)

Less than half of directors are independent

Chairman & MD recently bought ₹1.6m worth of stock

Investor sentiment deteriorated over the past week

Promoter & Whole-Time Director recently sold ₹10m worth of stock

Promoter & Whole-Time Director recently sold ₹3.2m worth of stock

Promoter & Whole-Time Director recently sold ₹2.8m worth of stock

Investor sentiment deteriorated over the past week

Shree Ram Proteins Limited, Annual General Meeting, Jul 18, 2022

Does Shree Ram Proteins (NSE:SRPL) Have A Healthy Balance Sheet?

Promoter & Whole-Time Director recently sold ₹11m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Chairman & MD recently sold ₹4.5m worth of stock

Investor sentiment deteriorated over the past week

Chairman & MD recently sold ₹2.8m worth of stock

Full year 2022 earnings released: EPS: ₹2.87 (vs ₹0.39 in FY 2021)

Chairman & MD recently sold ₹3.7m worth of stock

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Investor sentiment improved over the past week

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS ₹0.77 (vs ₹1.27 loss in 2Q 2021)

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Full year 2021 earnings released: EPS ₹0.39 (vs ₹1.22 in FY 2020)

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Third quarter 2021 earnings released: ₹0.16 loss per share (vs ₹0.22 loss in 3Q 2020)

New 90-day high: ₹37.35

Shree Ram Proteins Limited Announces Board Changes

New 90-day low: ₹29.55

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견